Blood test for tumor DNA in gastrointestinal cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a blood test (ctDNA) to look for genetic material from tumors in patients with gastrointestinal cancers. It may help doctors understand and track your cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are able to take care of yourself and do light activities (ECOG score 0 or 1).
- You have been diagnosed with a cancer of the esophagus, stomach, intestines, pancreas, or bile ducts.
- Your cancer is either removable by surgery, has spread to nearby areas, or has spread to distant parts of the body.
- You have a tumor tissue sample available from a previous biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.
This trial is studying a blood test that looks for tumor DNA (ctDNA) to see if it can help predict how well treatment is working in people with pancreatic cancer that hasn't spread. It is for patients getting chemotherapy before possible surgery.
This trial uses a blood test called ctDNA to look at the genetic makeup of your cancer. It aims to learn more about bile duct cancer and may help guide your treatment choices.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.